IMUNON’s IMNN-101 Vaccine Shows Promising Results in Phase 1 Trial, Demonstrates Cross-Reactivity Against COVID Variants
IMUNON, Inc, a clinical-stage company focused on developing non-viral DNA-based immunotherapies, has announced promising results from its Phase 1 proof-of-concept clinical trial of IMNN-101, a DNA plasmid vaccine targeting COVID-19. The vaccine, developed using the company’s proprietary PlaCCine technology, demonstrated a sustained immune response with a 2- to 4-fold increase in neutralizing antibody (NAb) titers […]
Measles-Positive New Mexico Resident Dies, Cause of Death Still Unconfirmed
This is a developing story and will be updated as more information becomes available. Update March 7, 1:01pm ET: The Texas Department of State Health Services is reporting there have been 198 cases of measles confirmed since late January. Twenty-three of the patients have been hospitalized.1 This means since Texas authorities last reported the number […]
Insights from Investigator Evaluating Paxlovid’s Effectiveness in Vaccinated Older Adults
Katherine L Kahn, MD Image credits: UC Health Randomized clinical trials of nirmatrelvir-ritonavir (Paxlovid) have shown reduced COVID-19-related hospitalizations in unvaccinated individuals, but its effectiveness in vaccinated populations remains unclear. This question is particularly important for older adults, who are at higher risk for severe COVID-19 outcomes. In an exclusive interview with investigator Katherine L […]
Key Study Findings and Future Plans
Vaxart, Inc recently published complete data from its Phase 1b trial of its first-generation oral norovirus vaccine, demonstrating encouraging results in elderly adults. The study showed that the vaccine was capable of inducing strong antibody and T-cell responses in adults aged 55-80, a group known to experience weakened immune responses to traditional injectable vaccines. The […]
Cautionary Tale Associated in Trial With Rare Error in Cox Regression
The German company InflaRx has developed an investigational therapy, vilobelimab, which is being studied for SARS-CoV-2-induced acute respiratory distress syndrome (ARDS). Vilobelimab is a first-in-class monoclonal antihuman complement factor C5a antibody. In one of its trials, the FDA recommended that the company use a site stratification adjustment. “We had the FDA recommending us to do […]
Vaxart Phase 1b Trial Shows 100% Increase in Serum Anti-VP1 IgA in Elderly Adults with Oral Norovirus Vaccine
Image credits: Vaxart Inc Vaxart, Inc announced the publication of complete data from its Phase 1b trial of its first-generation oral pill norovirus vaccine candidate in elderly adults. The trial demonstrated the vaccine’s ability to induce strong antibody and T-cell responses in adults aged 55-80, a population known to experience age-related declines in immune responses […]
Texas Outbreak Increases, Northeast Reports Cases, CDC Deployed to Help
On Tuesday, the Texas Department of State Health Services provided an update on the measles outbreak in there. Authorities reported there were 159 cases have been identified with 22 of the patients being hospitalized in western counties in the state. Gaines county has reported the highest number of cases with 107. There has been 1 […]
Invivyd’s Monoclonal Antibody Neutralizes Against Dominant COVID-19 Strain
Invivyd’s Chief Scientific Officer Robert Allen, PhDImage credit: Invivyd Today, Waltham, Mass.-based biopharmaceutical company,Invivyd, announced its monoclonal antibody, pemivibart (Pemgarda), continued to demonstrate neutralizing activity against the dominant strain of COVID-19, LP81. The variant did not generate any meaningful change to the neutralization activity of pemivibart or VYD2311, the company’s next generation COVID-19 monoclonal antibody […]
FDA Pauses BioNTech’s Malaria Vaccine Trial Amid Broader Vaccine Challenges
The FDA has paused BioNTech’s Phase I/IIa trial of its experimental malaria vaccine, BNT165e, due to unspecified concerns, the company confirmed in an SEC filing on Monday. BioNTech is working with the FDA to address the agency’s requests, though specific details have not been disclosed. Both parties are collaborating to determine the next steps for […]
Ivermectin Does Not Reach Primary Endpoint in Burkina Faso Malaria Trial
A large clinical trial in Burkina Faso found that repeated high-dose ivermectin mass drug administration (MDA) did not significantly reduce malaria incidence in children when integrated with seasonal malaria chemoprevention (SMC). The study, published in The Lancet, evaluated ivermectin’s safety and efficacy in killing malaria-carrying mosquitoes that feed on treated individuals. Despite its safety and […]
